The immunohistochemical staining of matrix metalloproteinases (MMPs) and E-cadherin in tumor epithelial and stromal cells was analyzed in a group of solid, superficial spreading and cystic tumors and in a group of morpheaform and recurrent basal cell carcinomas (BCC) in order to determine whether any of these factors possibly contribute to tumor therapy resistance. Tumor tissues of 64 patients were obtained by complete excisional or curettage biopsy of BCC and these were immunohistochemically stained for MMP-1, MMP-2, MMP-9, MMP-13 and E-cadherin. In the morpheaform and recurrent BCC, MMP-9 expression significantly increased in the stroma, while E-cadherin expression was negative in epithelial cells. Odds ratio for development of morpheaform and recurrent BCC was 6.2 for positive MMP-1 immunostaining in epithelial tumor cells, 5.8 for positive MMP-9 immunostaining in tumor stroma, 3.2 for positive MMP-13 immunostaining in tumor stroma, and 4.5 for negative E-cadherin in epithelial tumor cells. Our results suggest that MMP-1 immunostaining in tumor cells, MMP-9 expression in stromal cells, and absence of E-cadherin expression are associated with morpheaform and recurrent BCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acthis.2013.12.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Giant Morpheaform Basal Cell Carcinoma Mimicking Scarring Alopecia: Exception Prone to Neglect.
Dermatopathology (Basel)
June 2024
Dermatologic Clinic, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
A 74-year-old woman in good general health presented with a 5-year history of progressive hair loss over several years, interpreted as female androgenetic alopecia (AGA), and was treated with topical 5% Minoxidil without improvement. The patient's relevant medical history revealed infiltrating, triple-negative apocrine carcinoma of the right breast four years before, treated by quadrantectomy, radiation, lymphadenectomy and chemotherapy, with no recurrence at the last follow-up. On examination, there was an asymptomatic 15 × 15 cm firm and whitish area of scarring alopecia on the central scalp.
View Article and Find Full Text PDFClinical and Molecular Features of Morpheaform Basal Cell Carcinoma: A Systematic Review.
Curr Oncol
November 2023
Cancer Axis, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.
Basal cell carcinoma (BCC) is the most common skin cancer, with a lifetime risk currently approaching up to 40% in Caucasians. Among these, some clinical and pathological BCC variants pose a higher risk due to their more aggressive biological behavior. Morpheaform BCC (morBCC), also known as sclerosing, fibrosing, or morpheic BCC, represents up to 5-10% of all BCC.
View Article and Find Full Text PDFNon-melanoma skin cancer excision with frozen section histology.
Dan Med J
April 2023
Department of Plastic and Breast Surgery, Aarhus University Hospital, Denmark.
Introduction: We aimed to determine any risk factors associated with 12-month recurrence and non-radical tumour excision of non-melanoma skin cancer where the tumour has been excised with intraoperative, frozen-section (FS) histopathological assessment; and to examine if FS histopathological assessment may be recomended in certain patient categories.
Methods: The study was a single-centre retrospective cohort study based on information obtained from patient charts on those treated primarily with FS-aided excision in the 2017-2019 period. A multiple logistic regression model was used to identify risk factors related to non-radical excision.
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes.
Medicina (Kaunas)
February 2023
First Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54643 Thessaloniki, Greece.
The group of histopathologically aggressive BCC subtypes includes morpheaform, micronodular, infiltrative and metatypical BCC. Since these tumors are at increased risk of recurring, micrographically controlled surgery is considered the best therapeutic option. Although dermoscopy significantly improves the clinical recognition of BCC, scarce evidence exists on their dermoscopic criteria.
View Article and Find Full Text PDFFrom Morphea to Dermatofibrosarcoma Protuberans.
Acta Dermatovenerol Croat
September 2022
Marija Delaš Aždajić, MD, PhD, Department of Dermatology and Venereology Sestre milosrdnice University Hospital Center, Vinogradska cesta 29 , 10 000 Zagreb , Croatia ;
Article Synopsis
- - Morphea profunda (MP) is a chronic autoimmune disease that leads to restricted skin movement and discomfort, while dermatofibrosarcoma protuberans (DFSP) is a rare, slowly growing tumor that can invade deeper tissues and has a tendency to recur locally but rarely spreads to other parts of the body.
- - A 39-year-old female patient had a brownish lesion diagnosed as MP at 20, which later developed into palpable nodules, leading to further evaluation and a new diagnosis of DFSP after deep biopsy and immunohistochemical analysis.
- - The patient underwent complete surgical removal of the DFSP tumor, followed by additional excision due to inadequate initial margins, and has shown no signs of
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!